Eleven states covered all three GLP-1s approved for obesity treatment
Youve got two proven options which work: the weekly injection and the daily pill
Moreover, the comparison between DPP-4 inhibitors and placebo demonstrated no difference in their risk for MACE (RR = 0.99, 95% CI 0.931.06)
More than 70% said they support employers and insurance programs setting minimum requirements, including prior authorization, thresholds for body mass index or participation in wellness programs, for coverage of GLP-1s
Some patients benefit from the Precision Peptide Genetic Test, which identifies genetic variations in GLP-1 receptor sensitivity and other peptide pathways that influence how your body responds to medication
Journal of Food Science and Engineering, 2(3), 129-137